Streamlining CAR-T Trials: Effective Supply Chain and QC Testing Through Collaborative Partnerships

WEBINAR

This session explores how Vall d'Hebron Institute of Oncology (VHIO) — a research center in personalized medicine for oncology — collaborates with the Blood and Tissue Bank of Catalonia (BST) — developer of the GMP manufacturing process and quality control for the investigational cell therapy product —  and with contract testing labs to manufacture and release retroviral vector and CAR-T cell therapies for Phase 1 trials. With patient treatment timelines at stake, managing the end-to-end supply chain — from cell collection to final QC release — is critical. Presenters will share how they align on logistics, testing, and communication to reduce delays and maintain compliance, highlighting a shared commitment to delivering personalized cell therapies safely and on time.

In this webinar, you will:

• Learn how the Vall d'Hebron Institute of Oncology, CDMOs, and contract testing labs work together to streamline the retroviral vector and CAR-T supply chain from cell collection to therapy delivery.
• Gain insights into the critical role of quality control testing in retroviral vector and CAR-T therapy release, including best practices for ensuring compliance and maintaining patient safety throughout the process.